Zeltia Group

Zeltia S.A.: Report at 30 June 2006

    Madrid, Spain (ots/PRNewswire) -

    Corporate:

    - Zeltia performs 1-for-50 bonus issue

    - Group revenues amounted to 42.5 million euro.

    - Investment in R&D amounted to 24.4 million euro in the first half of 2006.

    - The net cash position (cash + cash equivalents + current financial assets - short-term borrowings) amounted to 55.3 million euro.

    PharmaMar:

    - Excellent results of Yondelis in myxoid liposarcomas and ovarian carcinoma presented at ASCO 2006

    NeuroPharma:

    - Progress with its first clinical-phase compound

    Zelnova:

    - Entered the Italian market by acquiring Copyr

      Isabel Lozano        Catherine Moukheibir M(a) Luisa de Francia
      Chief Executive    Head of Capital         Chief Financial Officer
      Officer                 Market Strategy
                                                                    ZELTIA, S.A.
      PHARMAMAR, S.A.    ZELTIA, S.A.
                                                                    José Abascal, 2. Madrid
      C/ Reyes, 1.         José Abascal, 2.
      Colmenar Viejo      Madrid                        Telephone +34-91-444-45-00
      Madrid                  Telephone
                                  +34-91-444-45-00
      Telephone
      +34-91-846-60-00

    For a copy of the full results, please refer to www.zeltia.com

ots Originaltext: Zeltia Group
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
Isabel Lozano, Chief Executive Officer, PHARMAMAR, S.A., C/Reyes, 1.
Colmenar Viejo, Madrid, Telephone +34-91-846-60-00, Catherine
Moukheibir, Head of Capital Market Strategy, ZELTIA, S.A., José
Abascal, 2. Madrid, Telephone +34-91-444-45-00, M(a) Luisa de
Francia, Chief Financial Officer, ZELTIA, S.A., José Abascal, 2.
Madrid, Telephone +34-91-444-45-00



Weitere Meldungen: Zeltia Group

Das könnte Sie auch interessieren: